{"analyses":[{"ciLowerLimit":"-6.0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"11.6","groupDescription":"6 Month Analysis","groupIds":["OG000","OG001"],"nonInferiorityComment":"Non-inferiority of the QD schedule relative to the BID schedule was deduced if the lower bound of the 95% confidence interval (CI) for the MCyRRQD minus MCyRRBID difference was greater than or equal to -15%.","nonInferiorityType":"NON_INFERIORITY_OR_EQUIVALENCE","paramType":"Risk Difference (RD)","paramValue":"2.8","testedNonInferiority":true}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.4","upperLimit":"58.2","value":"51.8"},{"groupId":"OG001","lowerLimit":"42.7","upperLimit":"55.4","value":"49.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"247"},{"groupId":"OG001","value":"251"}],"units":"Participants"}],"description":"Cytogenetic response (CyR) was based on the number of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a Bone Marrow (BM) sample. The criteria for CyR were as follows: Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM; Partial cytogenetic response (PCyR): \\>0 to 35% Ph+ cells in metaphase in BM; Minor cytogenetic response: \\>35 to 65% Ph+ cells in metaphase in BM; Minimal cytogenetic response: \\>65 to 95% Ph+ cells in metaphase in BM; No cytogenetic response: \\>95 to 100% Ph+ cells in metaphase in BM; Best CyR was defined as the best response obtained at any time during the study; MCyR was defined as a best CyR of complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Baseline=closest to, but no later than, the first day of study drug for treated participants and closest to, but no later than, the date of randomization, for those who were randomized but who never received treatment, unless otherwise specified.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received either 100 mg or 140 mg once a day (QD) dasatinib until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG000","title":"QD Dasatinib"},{"description":"Participants received either 50 mg or 70 mg twice a day (BID) dasatinib until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG001","title":"BID Dasatinib"}],"paramType":"NUMBER","populationDescription":"All randomized imatinib-resistant participants with available data were summarized.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Percent of Participants With Major Cytogenetic Response (MCyR) at 6 Months Follow-Up","type":"PRIMARY","unitOfMeasure":"percentage of Participants"}